AcelRx Pharma (ACRX) Reports In-Line Q4 EPS, Revenues Miss

FREE Breaking News Alerts from StreetInsider.com!

E-mail Address

StreetInsider.com Top Tickers, 10/27/2026

1. ORCL
2. META
3. SPY
4. ANT
5. CART
6. FFAI
7. TSLA
8. FFR
9. XNCR
10. AZN

Go back to AcelRx Pharma (ACRX) Reports In-Line Q4 EPS, Revenues Miss

AcelRx Pharmaceuticals Reports Fourth Quarter and Full Year 2020 Financial Results

March 15, 2021 4:01 PM EDT

REDWOOD CITY, Calif., March 15, 2021 /PRNewswire/ -- AcelRx Pharmaceuticals, Inc. (Nasdaq: ACRX), (AcelRx), a specialty pharmaceutical company focused on the development and commercialization of innovative therapies for use in medically supervised settings, today reported its fourth quarter and full year 2020 financial results.

"Last year we achieved many important milestones and objectives that set the foundation for the growth of DSUVIA® in 2021 and beyond, despite the global pandemic," said Vince Angotti, Chief Executive Officer of AcelRx. "Like many other companies in our space, COVID has had an impact on the... More